Jayashree Dutta
Gauhati University, India
Title: In vitro and in vivo hypoglycemic evaluation of Terminalia chebula Retz leaves
Biography
Biography: Jayashree Dutta
Abstract
Diabetes mellitus is one of the fast-growing health problems in both developing and developed nations. A wide and diverse range of plants reported in Indian literature are used in the treatment of diabetes mellitus. Being a store house of medicinal plants, the north-eastern part of India serves as reservoir of traditional based knowledge for treatment of several diseases including diabetes. In the present study, the leave part of Terminalia chebula Retz was accessed for its hypoglycemic potentiality both in vitro and in vivo. Initial in vitro test was performed using enzyme α-amylase and α-glucosidase. In vitro analysis was followed by in vivo hypoglycemic evaluation in alloxan induced diabetic rat model. Terminalia chebula leaves has demonstrated a moderate level of α-amylase inhibition (70.46%) with IC50-06.09±0.342 mg/mL and very high yeast α-glucosidase inhibition (100%) with IC50-0.956±0.342 mg/mL compared to standard reference drug acarbose. Oral carbohydrate tolerance test of methanol extract T. chebula leaves revealed that oral administration of the extract at the dose of (300 mg/kg b.w) to maltose loaded diabetic rats significantly (P<0.05) suppressed the rise of post-prandial blood glucose level compared to the standard drug acarbose. The phytochemical analysis reveals that the crude methanol extract of T. chebula leaves is very rich in phytoconstituents like phenol, tannin flavonoids, terpenoid and glycosides compared to petroleum ether extract and acetone extract. The total phenol and flavonoid content of T. chebula leaves was found to be 123.64±1.09 mg/g and 184.23±2.34 mg/g respectively. The study concludes that the leaf part of T. chebula is a potential inhibitor of enzyme α-glucosidase that can be employed for further for development of suitable anti-diabetic formulation working against postprandial hyperglycemia.